BIFIDO Co. Ltd (238200) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BIFIDO Co. Ltd (238200) has a cash flow conversion efficiency ratio of -0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-31.26 Million ≈ $-21.19K USD) by net assets (₩44.44 Billion ≈ $30.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View 238200 live share price for real-time trading data and today's change.
BIFIDO Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how BIFIDO Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market cap of BIFIDO Co. Ltd for the company's overall valuation and market capitalisation.
BIFIDO Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIFIDO Co. Ltd ranked by their cash flow conversion efficiency. Also see BIFIDO Co. Ltd asset portfolio for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CAS Corporation
KQ:016920
|
0.034x |
|
CSLM Acquisition Corp.
NASDAQ:CSLMF
|
-0.046x |
|
4Imprint Group Plc
LSE:FOUR
|
0.566x |
|
Olympia Industries Bhd
KLSE:3018
|
0.024x |
|
All In! Games S.A.
WAR:ALG
|
-0.028x |
|
Jaycorp Bhd
KLSE:7152
|
-0.009x |
|
GETS Global Bhd
KLSE:5079
|
-0.070x |
|
Gold Springs Resource Corp
TO:GRC
|
-0.004x |
Annual Cash Flow Conversion Efficiency for BIFIDO Co. Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of BIFIDO Co. Ltd from 2016 to 2025. Review BIFIDO Co. Ltd free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩45.93 Billion ≈ $31.13 Million |
₩3.95 Billion ≈ $2.68 Million |
0.086x | +660.57% |
| 2024-12-31 | ₩46.69 Billion ≈ $31.64 Million |
₩-716.29 Million ≈ $-485.42K |
-0.015x | -127.85% |
| 2023-12-31 | ₩51.70 Billion ≈ $35.04 Million |
₩2.85 Billion ≈ $1.93 Million |
0.055x | +54.19% |
| 2022-12-31 | ₩52.49 Billion ≈ $35.57 Million |
₩1.88 Billion ≈ $1.27 Million |
0.036x | -11.12% |
| 2021-12-31 | ₩50.64 Billion ≈ $34.32 Million |
₩2.04 Billion ≈ $1.38 Million |
0.040x | -3.97% |
| 2020-12-31 | ₩44.60 Billion ≈ $30.22 Million |
₩1.87 Billion ≈ $1.27 Million |
0.042x | -26.86% |
| 2019-12-31 | ₩46.29 Billion ≈ $31.37 Million |
₩2.65 Billion ≈ $1.80 Million |
0.057x | -46.13% |
| 2018-12-31 | ₩44.73 Billion ≈ $30.31 Million |
₩4.75 Billion ≈ $3.22 Million |
0.106x | -49.13% |
| 2017-12-31 | ₩18.50 Billion ≈ $12.53 Million |
₩3.86 Billion ≈ $2.62 Million |
0.209x | +0.49% |
| 2016-12-31 | ₩16.07 Billion ≈ $10.89 Million |
₩3.34 Billion ≈ $2.26 Million |
0.208x | -- |
About BIFIDO Co. Ltd
BIFIDO Co., Ltd. produces probiotics-based products in South Korea and internationally. It offers bifidobacterium strain products, such as BGN4 for immune modulating; BORI used to treat rotavirus infection in infants; and AD011 for general intestinal health problems. The company was founded in 1999 and is headquartered in Hongcheon-eup, South Korea.